- Home
- XERS vs MGTX Comparison
XERS vs MGTX Comparison
Compare XERS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- MGTX
- Stock Information
- Founded
- XERS 2005
- MGTX 2015
- Country
- XERS United States
- MGTX United States
- Employees
- XERS N/A
- MGTX N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XERS Health Care
- MGTX Health Care
- Exchange
- XERS Nasdaq
- MGTX Nasdaq
- Market Cap
- XERS 752.7M
- MGTX 622.0M
- IPO Year
- XERS 2018
- MGTX N/A
- Fundamental
- Price
- XERS $5.49
- MGTX $7.83
- Analyst Decision
- XERS Strong Buy
- MGTX Strong Buy
- Analyst Count
- XERS 6
- MGTX 2
- Target Price
- XERS $6.25
- MGTX $24.00
- AVG Volume (30 Days)
- XERS 1.8M
- MGTX 658.8K
- Earning Date
- XERS 08-07-2025
- MGTX 08-11-2025
- Dividend Yield
- XERS N/A
- MGTX N/A
- EPS Growth
- XERS N/A
- MGTX N/A
- EPS
- XERS N/A
- MGTX N/A
- Revenue
- XERS $222,551,000.00
- MGTX $34,508,000.00
- Revenue This Year
- XERS $35.31
- MGTX $228.65
- Revenue Next Year
- XERS $19.65
- MGTX $145.06
- P/E Ratio
- XERS N/A
- MGTX N/A
- Revenue Growth
- XERS 29.88
- MGTX 203.23
- 52 Week Low
- XERS $2.10
- MGTX $3.85
- 52 Week High
- XERS $6.07
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- XERS 62.75
- MGTX 48.93
- Support Level
- XERS $4.94
- MGTX $7.44
- Resistance Level
- XERS $5.22
- MGTX $8.31
- Average True Range (ATR)
- XERS 0.22
- MGTX 0.37
- MACD
- XERS -0.01
- MGTX -0.18
- Stochastic Oscillator
- XERS 86.44
- MGTX 21.85
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.